Post by JHam on Mar 27, 2019 5:26:34 GMT
They have a CC tomorrow morning before the open to update shareholders on a meeting with the FDA regarding their P3 and a data update on their P1/2 trial.
Low market cap ($23M)
Low float (6.8M)
So if the news is positive it could go on a run. A risky binary event so as always, do your own DD. Just thought I'd bring it your attention in case anyone is feeling like living on the edge
finance.yahoo.com/news/fibrocell-host-conference-call-webcast-120000949.html?.tsrc=rss
- Company to provide update on Type B meeting with FDA on Phase 3 clinical trial design for FCX-007 gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB) -
- Company to highlight updated data from ongoing FCX-007 Phase 1/2 clinical trial for RDEB -
Low market cap ($23M)
Low float (6.8M)
So if the news is positive it could go on a run. A risky binary event so as always, do your own DD. Just thought I'd bring it your attention in case anyone is feeling like living on the edge
finance.yahoo.com/news/fibrocell-host-conference-call-webcast-120000949.html?.tsrc=rss
- Company to provide update on Type B meeting with FDA on Phase 3 clinical trial design for FCX-007 gene therapy candidate for recessive dystrophic epidermolysis bullosa (RDEB) -
- Company to highlight updated data from ongoing FCX-007 Phase 1/2 clinical trial for RDEB -
